Pliant Therapeutics expands board to nine, appoints two new directors
Effective July 9, 2026, Pliant Therapeutics increased its board from seven to nine members and appointed Robert Iannone, M.D., M.S.C.E., and Flavia Borellini, Ph.D., as directors. Borellini will chair the R&D Committee, and Iannone will join it. The filing describes director pay and stock options but does not report any financial results or changes to company operations.
Key points
- Board size increased from seven to nine members, effective July 9, 2026.
- Robert Iannone, M.D., M.S.C.E., appointed as a Class I director; Flavia Borellini, Ph.D., appointed as a Class II director.
- Borellini named chairperson of the R&D Committee; Iannone named a member.
- Each new director receives a $40,000 annual retainer and an option for 60,000 shares vesting over three years. Iannone receives an extra $7,500 retainer and Borellini an extra $15,000 for committee roles.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.